WO1997045437A1 - Compositions and methods for antisense inhibition of protein translation - Google Patents
Compositions and methods for antisense inhibition of protein translation Download PDFInfo
- Publication number
- WO1997045437A1 WO1997045437A1 PCT/US1997/007132 US9707132W WO9745437A1 WO 1997045437 A1 WO1997045437 A1 WO 1997045437A1 US 9707132 W US9707132 W US 9707132W WO 9745437 A1 WO9745437 A1 WO 9745437A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligomer
- seq
- target mrna
- och
- isis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3531—Hydrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- United States Patent application 08/653,653 is also a contmuation-m-part of United States patent application 07/927,506 filed on November 19, 1992, which is a contmuation- m-part application of United States Patent application 07/568,366 filed on August 16, 1990.
- This invention is directed to methods for inhibiting gene expression via interference with protein translation.
- the invention generally relates to the field of antisense inhibition of gene expression.
- Antisense methodology is the complementary hybridization of relatively short oligomers, usually oligonucleotides or oligonucleosides, to mRNA or DNA, such that the normal, essential functions of these target nucleic acids are disrupted.
- Hybridization is the sequence specific hydrogen bonding of nucleobases on the oligomer to RNA or single stranded DNA according to the rules of Watson-Crick base pairing. Members of such base pairs are said to be complementary to one another.
- Oligonucleotides have already been employed as therapeutic moieties in the treatment of disease states in animals and man.
- Antisense oligomer compositions have been shown to be capable of modulating expression of genes implicated in viral, fungal and metabolic diseases. Further, antisense oligonucleotides have been safely administered to humans and clinical trials of a dozen or more antisense drugs, targeted to viral and cellular gene products, have been initiated. Clinical efficacy has been demonstrated in several human trials, for both viral and cellular disease targets.
- the present invention provides new antisense compounds and compositions together with methodologies for the use of certain antisense compounds for interfering with translation of selected mRNA targets.
- antisense approaches utilize antisense oligonucleotides targeted to the AUG, or, less often, the 5'- untranslated region, 5' cap, 3 ' -untranslated region, coding or other regions of mRNA. Helene and Toulme, Biochem . et Biophy ⁇ .
- RNAse H is a cellular endonuclease that cleaves the RNA strand of RNA:DNA duplexes; activation of this enzyme therefore results in cleavage of the RNA target, and thus can greatly enhance the efficiency of antisense inhibition.
- Cleavage of the RNA target can be routinely demonstrated by gel electrophoresis or Northern blotting showing a decrease in target mRNA abundance, and/or direct visualization of the cleavage products.
- Phosphorothioate oligodeoxynucleotides are substrates for RNAse H; however, some antisense oligomers, such as PNAs, oligonucleosides and oligonucleotides which are uniformly modified at the 2' position of the sugar, do not activate RNAse H. Kawasaki et al.,. J. Med Chem . 1993, 36, 831-841. Often a sequence which is highly active as a phosphorothioate oligodeoxynucleotide is inactive when made as an analog which is not a substrate for RNAse H. This may be true even if the affinity of the oligonucleotide for the target is increased by such a modification. Helene and Toulme, Biochem . et Biophys . Acta 1990, 1049, 109.
- oligomers which specifically hybridize to the 5' cap region of their target mRNA have been found to be surprisingly active in interfering with translation of the target mRNA into protein.
- These oligomers include peptide-nucleic acid (PNA) oligomers, oligonucleosides (such as those having an MMI , amide or morpholino backbone) and oligonucleotides having modifications at the 2' position of the sugar.
- PNA peptide-nucleic acid
- oligonucleosides such as those having an MMI , amide or morpholino backbone
- oligonucleotides having modifications at the 2' position of the sugar.
- This invention provides methods for inhibiting the translation of a selected capped target mRNA by contacting the target mRNA with an antisense oligomer which is 8-25 bases in length and which is complementary to the 5' cap region of the target mRNA.
- the oligomer may be a 2 '-modified oligonucleotide, an oligonucleoside, or a peptide-nucleic acid oligomer.
- Preferred oligonucleosides include those having morpholino, amide or MMI internucleoside linkages.
- Peptide-nucleic acid oligomers are also preferred.
- oligomers which specifically hybridize to the 5' cap region of their specific target mRNA have been found to be surprisingly active in interfering with translation of the target mRNA into protein.
- oligomers include peptide-nucleic acid (PNA) oligomers, oligonucleosides (which have a non-phosphorous backbone such as an amide, morpholino or MMI backbone) and oligonucleotides having 2' -modifications. These oligomers are designed to be specifically hybridizable with the 5' cap region of the target mRNA.
- PNA peptide-nucleic acid
- oligonucleosides which have a non-phosphorous backbone such as an amide, morpholino or MMI backbone
- oligonucleotides having 2' -modifications are designed to be specifically hybridizable with the 5' cap region of the target mRNA.
- Figure 1 is a set of line graphs showing the reduction of ICAM-1 protein levels by 2' modified oligomers targeted to the 5' cap of ICAM-1.
- Figure 1A shows the activity of phosphodiester compounds;
- Figure IB shows the phosphorothioate compounds.
- Figure 2 is a bar graph of a Northern blot showing a significant increase in the relative abundance of the ICAM-1 transcript in cells treated with the anti-ICAM-1 oligonucleomers ISIS 11158 and 11159.
- Figure 3 is a line graph showing the ability of 2' modified oligomers targeted to the 5' cap region of the E- selectin mRNA to inhibit E-selectin expression in HUVECs .
- Figure 4 is a line graph showing inhibition of ICAM-1 expression in HUVECs by oligonucleotides targeting the 5' cap region of ICAM-1. Solid squares: ISIS 11158; Open diamonds: ISIS-13884; Closed circles; ISIS 13886.
- Figure 5 is a line graph showing inhibition of E-selectin expression in HUVECs by oligonucleotides targeting the 5' cap region of E-selectin.
- Figure 6 is a line graph showing inhibition of VCAM-1 expression in HUVECs by oligonucleotides targeting the 5' cap region of VCAM-1.
- RNAs and messenger RNAs have a unique chemical structure at their 5' terminus which is required in varying degrees for their maturation, stability, and efficiency of translation.
- the general structural features are given in S. Cory and JM Adams, J. Mol . Biol . 1975, 99, 519-547.
- the cap is a guanosine residue which is methylated at the nitrogen 7 position. It is joined to the 5'-most transcribed nucleotide of the RNA via a triphosphate linkage between the 5' hydroxyl groups of each residue.
- the antisense oligomers in accordance with this invention specifically hybridize with a capped target mRNA transcript at its 5' end.
- the oligomers will bind to a region including at least one of the first 20 nucleotides at the 5' end of the target mRNA, where the first nucleotide is adjacent to the 5' cap and connected to the methylated guanosine of the cap via the triphosphate linkage described supra . More preferably, the oligomers will bind to a region including at least one of the first five nucleotides at the 5' end of the target mRNA.
- the oligomers of the present invention preferably are from about 5 to about 50 bases in length. Oligomers from about 8 to 25 bases in length are more preferred.
- oligomer is intended to encompass oligonucleotides, oligonucleotide analogs, oligonucleosides or oligonucleotide-mimickmg macro- molecules, all of which have heterocyclic bases (nucleobases) positioned thereon which are capable of specifically hybridizing to a complementary base sequence.
- This term includes oligomers consisting of naturally occurring bases, sugars and mtersugar (backbone) linkages, as well as oligomers having non-naturally occurring portions which function similarly.
- modified or substituted oligomers are often preferred over native forms because of properties such as, for example, enhanced cellular uptake, increased stability in the presence of nucleases and/or increased affinity for a complementary target sequence.
- Affinity of an oligomer for its target is routinely determined by measuring the Tm of an oligomer/target pair, which is the temperature at which the oligomer and target dissociate; dissociation is detected spectrophotometrically. The higher the Tm, the greater the affinity of the oligomer for the target.
- oligonucleosides which contain non- phosphorus mtersugar linkages, for example short chain heteroatomic or heterocyclic mtersugar linkages.
- Most preferred are those with CH 2 -NH-0-CH 2 , CH 2 -N(CH 3 ) -0-CH 2 [known as the methylene (methylimmo) or MMI backbone] , CH 2 -0-N(CH 3 ) -CH 2 , CH 2 -N(CH 3 ) -N(CH 3 ) -CH 2 and 0-N(CH 3 ) -CH 2 -CH 2 backbones (where phosphodiester is 0-P-0-CH 2 ) .
- amide backbones of De Mesmaeker et al . , Ace . Chem . Res . 1995, 28, 366-374. Of these, CH ? -CO-NR-CH 2 , also called amide- 3, and CH 2 -NH-CO-CH 2 , also called am ⁇ de-4, are more preferred. Also preferred are oligomers having morpholino backbone structures (Summerton, J.E. and Weller, D.D., U.S.
- Patent 5,034,506 a phosphodiester backbone of a native oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (P.E. Nielsen, M. Egholm, R.H. Berg, 0. Buchardt, Science 1991, 254, 1497) .
- oligomers are oligonucleotides having modifications on one or more sugar moieties, preferably at the 2' position.
- suitable 2' modifications are C x to C 10 lower alkyl, substituted lower alkyl, alkoxyalkoxy, alkaryl or aralkyl; F; Cl; Br; CN; CF 3 ; OCF 3 ; 0-, S-, or N- alkyl; SH, SCH 3 , OCN, alkylamines such as 0(CH 2 ) n NH 2 where n is from 1 to about 10; 0(CH 2 ) n CH 3 where n is from 1 to about 10; or other groups which improve the pharmacokinetic or pharmacodynamic properties of the oligomer or the affinity of the.
- oligomer for its target, or which stabilize the oligomer.
- more preferred oligomers include MMI and morpholino oligonucleosides, PNAs, 2'-F, 2'-0-alkyl, preferably 2'-0-CH 3 and 2' -0-CH 2 CH 2 CH 3 , and 2 ' -alkoxyalkoxy oligonucleotides, most preferably, 2 ' -0CH 2 CH 2 0CH 3 [also known as 2' -0- (2-methoxyethyl) or 2' -methoxyethoxy] . It is not necessary that the oligomer be uniformly modified in the aforementioned way(s) .
- Oligomers with at least one modified nucleobase are also comprehended by the invention.
- oligomers used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for solid or liquid phase synthesis may also be employed; synthesis of the oligomers is well within the talents of the routineer. It is well known to use these techniques to prepare 2'-modified oligonucleotides, backbone-modified oligomers and other oligomers.
- a capped target mRNA is contacted with an oligomer.
- a "target" mRNA is the mRNA whose translation is to be specifically inhibited through antisense interaction.
- the antisense oligomers of the invention are designed to be specifically hybridizable with a complementary nucleotide sequence on their mRNA target.
- target or “target region” also encompasses this sequence of the mRNA, i.e., the particular region to which the antisense oligomer is complementary.
- to "contact" a target rnRNA with an oligomer means to add the oligomer, either in vi tro or ex vivo, to a cell suspension or tissue sample containing or suspected of containing said target mRNA, or to administer the oligomer to cells or tissues within an animal which contain or are suspected to contain the target mRNA.
- the oligomer is usually in a liquid carrier or part of a pharmaceutical composition which may contain additional ingredients in addition to carrier.
- Hybridization in the context of this invention, means hydrogen bonding, also known as Watson-Crick base pairing, between complementary nucleobases. Guanine and cytosme are examples of complementary bases which are known to form three hydrogen bonds between them. Adenine and thymme are examples of complementary bases which form two hydrogen bonds between them. Triple-strand formation, or triplexmg, is a particular form of hybridization of an oligomer to a double-stranded region of the target, such as a hairpin region on an RNA molecule. "Specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the RNA target and the oligomer.
- an oligomer need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable.
- An oligomer is specifically hybridizable when binding of the oligomer to the target interferes with the normal function of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligomer to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or, in the case of in vi tro assays, under conditions in which the assays are conducted.
- the oligomers of the invention are designed to be specifically hybridizable with the 5' cap region of a capped target mRNA.
- 5' cap region refers to the region of said target mRNA which includes at least one of the first 20 bases at the 5' terminus of said target mRNA. In other words, at least one of nucleotides 1-20 where nucleotide number 1 is adjacent to the cap structure.
- ICAM-1 ICAM-1
- ICAM-1 intercellular adhesion molecule-1
- ICAM-1 is one of several cell adhesion molecules expressed on the surface of vascular endothelium and participates in a variety of immune and inflammatory responses. ICAM-1 is also expressed on non- endothelial cells in response to inflammatory mediators. Elevated levels of ICAM-1 expression have been observed in a number of disease states such as rheumatoid arthritis and psoriasis, and ICAM-1 has become a target of therapeutic interest. Clinical trials are presently underway for an antisense oligonucleotide that inhibits the expression of human
- ICAM-1 in patients with a variety of disease conditions: rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis and prevention of renal transplant rejection. Efficacy has already been demonstrated in a Phase II trial of this drug, ISIS 2302, in Crohn's disease. Genetic Engineering News, March 1, 1997, pg. 1; New York Times, Friday, February 28, 1997. It has now been found that RNAse H activity is not necessary for good antisense activity when antisense oligomers are targeted to the 5' cap region of the ICAM-1 transcript.
- oligomers which do not activate RNAse H, or at least are RNAse H-independent have been found to be surprisingly active when targeted to this region.
- Data were obtained for fully 2'-modified oligomers which are not substrates for RNAse H.
- the target region was nucleotides 1-20 (where nucleotide 1 is immediately adjacent to the cap structure) of the ICAM-1 transcript.
- a dose response analysis of nine different oligomers was performed to determine their efficacy for inhibition of ICAM-1 cell surface protein expression in comparison to a phosphorothioate deoxyoligonucleotide, ISIS 3067 (SEQ ID NO: 1; TCTGAGTAGCAGAGGAGCTC) , targeted to the same region. This compound had previously been shown to be very effective at inhibition of ICAM-1 expression.
- WO 92/03139 (Bennett et al . ) , J. Immunol . (1994) 152:3530-3540.
- the oligomers studied were 2' -methoxy (also referred to as 2 ' -O-methyl) , 2 ' -propoxy (also referred to as 2 ' -0-propyl) , 2'-
- ISIS 11159 ISIS 11159
- ISIS 11158 The phosphodiester 2' -methoxyethoxy compound, ISIS 11158, had an IC50 of approximately 9 nM. This compound is also preferred.
- Northern blot analysis showed a significant increase in the relative abundance of the ICAM-1 transcript in cells treated with the anti-ICAM-1 oligonucleotides (ISIS 11158 and 11159) . This is shown in Figure 2. ICAM-1 protein expression was completely inhibited at these oligonucleotide concentrations.
- ISIS 11929 is an antisense oligonucleotide targeted to E- selectin, another cellular adhesion molecule, and was included in this experiment as a control. Treatment of cells with ISIS
- ICAM-1 protein and mRNA levels were measured after treatment with ISIS 11159 or ISIS 12345
- control Cell surface expression of ICAM-1 protein was determined by FACS analysis of a small portion of treated cells; ISIS 11159 was found to reduce ICAM-1 levels by 84% compared to untreated controls. The scrambled control oligomer ISIS 12345 reduced ICAM expression by only 3%. Cytosolic extracts of the remaining cells were prepared and sedimented by sucrose gradient centrifugation. Gradients were fractionated, RNA was isolated from each fraction and analyzed on a 1% denaturing agarose gel to demonstrate acceptable separation of the subpolysomal and polysomal pools.
- ICAM-1 transcript Determination of the distribution of the ICAM-1 transcript by northern blotting showed a significant difference in the polysome profile for ISIS 11159 treated cells compared to cells treated with the control oligomer ISIS 12345 or untreated control cells.
- the ISIS 11159 showed the majority (67%) of the full-length ICAM-1 transcript localized in the subpolysome fraction (40S, 60S and 80S ribosome fractions) whereas the control ISIS 12345-treated and untreated cells showed the ma ⁇ onty (73% and 69% respectively) of the full length ICAM-1 transcript in the polysome fractions. This demonstrates that ISIS 11159 is interfering with translation directly, by interfering with ribosome assembly onto the target mRNA.
- PNA oligomers targeted to the 5' cap have also been shown to inhibit ICAM-1 expression.
- a PNA oligomer, ISIS 10535 (SEQ ID NO: 2) was synthesized, which is a shortened version of SEQ ID NO: 1 made as a PNA, with three arginines added at the 5' end and one lysine added at the 3' end. This oligomer was electroporated into U937 cells and a potent dose-response was obtained. ICAM-1 was reduced to below baseline levels at higher doses of ISIS 10535.
- ISIS 10535 had an IC50 of less than 5 ⁇ M and ISIS 3067 had an IC50 of over 20 ⁇ M. Therefore, ISIS 10535 is preferred.
- E-selectin Other adhesion molecules have been identified which are involved in the adherence of white blood cells to vascular endothelium and subsequent migration out of the vasculature. One of these is E-selectin, also known as endothelial leukocyte adhesion molecule-1 (ELAM-1) .
- ELAM-1 endothelial leukocyte adhesion molecule-1
- oligonucleotide sequences complementary to various regions of the E-selectin message (5' cap, 5' UTR, AUG, coding region, intron, 3' UTR) , by far the most active was ISIS 9984 (SEQ ID NO: 3; GAAGTCAGCCAAGAACAGCT) , targeted to the 5' cap region (nucleotides 1-20) of the human E-selectin mRNA.
- the human CMV genome is the most complex of the herpes viruses in terms of its genomic structure. Replication- defective mutants of human CMV have only been isolated for two viral genes, the immediate early complex (IE1/IE2) and the DNA poly ⁇ nerase. These genes are known to play major roles in human CMV gene expression. They have been selected as primary targets for antisense compound design.
- IE1/IE2 immediate early complex
- IE1/IE2 DNA poly ⁇ nerase
- CMV has been as well elucidated as that of any transcriptional unit in the eucaryotic cell.
- IE1 major immediate early transcript
- the IE1/IE2 mRNA is an abundant capped RNA which encodes both IE1 and IE2 proteins, by differential splicing of the mRNA.
- IE1 controls the expression of itself as well as that of the IE2 gene product.
- IE2 mRNA is made by processing of the IE1 mRNA during this early time of infection.
- the IE2 protein is capable of transcriptionally activating many of the CMV early and late genes in a manner similar to other known transactivatmg proteins of cellular and viral origin. Thus, the IE2 protein is believed to be one of the master switches for CMV gene expression.
- An antisense drug targeted to CMV IE2 mRNA is presently in clinical trials and has been shown to be active against CMV retmitis m AIDS patients.
- the sequence of the CMV IE1/IE2 mRNA transcript is known (Stenberg, R.M., Witte, P.R. and Stmski, M.F., J. Virol . 1985, 56, 665-675; Stenberg, R.M. , Thomsen, D.R., and Stmski, M.F., J. Virol . 1984, 49: 190-199) .
- the 5' end of the mRNA is now known to terminate with a "G" (oligonucleotides 1-21 are shown) :
- Oligonucleotides having IC50s of 1 ⁇ M or below in Table 2 are preferred.
- Oligonucleotides were directly tested for ability to inhibit expression of IE1 and IE2 protein products in stably transfected U373 neuroblastoma cells expressing a single CMV protein.
- IE1 is translated into a 72kD polypeptide product.
- IE2 is differentially spliced into two polypeptide products, a 55kD product and an 86 kD product.
- TGGATGGCGTCTCCAGGCGA SEQ ID NO: 8
- ISIS 3300 (SEQ ID NO: 5) was found to inhibit expression of the 72kD protein with an IC50 of approximately 75 nM.
- antisense oligomers targeting the 5' terminus of the CMV IE1/IE2 mRNA can effectively inhibit synthesis of multiple protein products of this transcript. Additional oligomers targeted to ICAM-1
- the oligomers shown in Table 3 were tested for their ability to inhibit human ICAM-1 protein expression in human umbilical vein endothelial cells (HUVECs) as described in
- Example 7 except that the human ICAM-1 monoclonal antibody mAb84H10 (AMAC Inc., Westbrook ME) was used. Bennett et al.
- ISIS 13884 When the phosphodiester/2 ' -methoxyethoxy (PO/2'MOE) oligomers ISIS 13884 and 13886 were tested in this assay, ISIS 13884 was found to have an IC50 of approximately 40 nM. ISIS 13886 was tested only up to concentrations of 50 nM and an IC50 was not obtained at this low dose. However, extrapolation of the dose-response curve gave an estimated IC50 of approximately 60 nM. This is shown in Figure 4. Both ISIS 13884 and 13886 are preferred embodiments of the present invention. For comparison, the phosphodiester 2' -methoxyethoxy compound, ISIS 11158, targeted to the extreme 5' end of the ICAM-1 message, had an IC50 of approximately 5 nM in the same experiment.
- ISIS 14289 (SEQ ID NO: 1) is a 20mer and ISIS 14290, 14291 and 14292 are progressively shortened versions of this sequence.
- Antisense activity (IC50) of these oligomers was determined by measurement of cell surface expression of ICAM-1 protein following treatment with each oligomer at six concentrations in the range of 4 to 40 ⁇ M for delivery by electroporation into U937 cells, and 6.2 to 200 nM for delivery by Lipofectin into HUVECs. "N.A.” indicates that an IC50 was not obtained in the given dose range. The results are shown in Table 4 :
- oligomers targeted to the 5' cap region of human E-selectin have been designed and tested for the ability to reduce E-selectin expression. These oligomers are shown in Table 5. Table 5 Oligomers targeted to the 5' cap region of E-selectin
- ISIS 4764 again demonstrated an IC50 of 10 nM.
- ISIS 11929, 11928, and 11205 again gave IC50s which were too low to measure, i.e., well below 3 nM.
- VCAM-1 VCAM-1
- Vascular cell adhesion molecule-1 like ICAM-1, is a member of the immunoglobulin gene superfamily. Also like ICAM-1 and E-selectin, VCAM-1 is induced on the luminal surface of vascular endothelium in response to inflammatory stimuli.
- oligomers targeted to the 5' cap region of human VCAM-1 were designed and synthesized, using the VCAM-1 sequence published by Cybulsky et al . (1991) Proc . Natl . Acad. Sci . , USA, 88:7859-7863. These oligomers are shown in Table 7. In these oligomers the nucleotide at the 3' end of the oligomer was a 2' -deoxynucleotide for ease of synthesis.
- Unmodified oligodeoxynucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine, ( ⁇ -cyanoethyldiisopropyl-phosphoramidites are purchased from Applied Biosystems (Foster City, CA) .
- Applied Biosystems model 380B standard phosphoramidite chemistry with oxidation by iodine, ( ⁇ -cyanoethyldiisopropyl-phosphoramidites are purchased from Applied Biosystems (Foster City, CA) .
- the standard oxidation bottle is replaced by a 0.2 M solution of 3 H-1, 2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages.
- the thiation cycle wait step is increased to 68 seconds and is followed by the capping step
- 2'-methoxy oligonucleotides are synthesized using 2'- methoxy / ⁇ -cyanoethyldiisopropyl-phosphoramidites (Chemgenes, Needham MA) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base is increased to 360 seconds.
- alkoxy oligonucleotides are synthesized by a modification of this method, using appropriate 2'-modified amidites such as those available from Glen Research, Inc., Sterling, VA.
- 2' -fluoro oligonucleotides are synthesized as described in Kawasaki et al . , J. Med. Chem . 1993, 36, 831-841. Briefly, the protected nucleoside N 6 -benzoyl-2' -deoxy-2' -fluoroadenosme was synthesized utilizing commercially available 9- ⁇ -D- arabmofuranosyladenine as starting material and by modifying literature procedures whereby the 2'- ⁇ -fluoro atom is introduced by a S N 2-displacement of a 2' - ⁇ -0-t ⁇ fyl group.
- TPDS tetraisopropyldisiloxanyl
- 9- ⁇ -D-arab ⁇ nofuranosylguanme 9- ⁇ -D-arab ⁇ nofuranosylguanme
- c o n v e r s i o n t o t h e i n t e r m e d i a t e diisobutyrylarabmofuranosylguanosme Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give dnsobutyryl di-THP protected arabmofuranosylguanme.
- Synthesis of 2' -deoxy-2' -fluorouridme was accomplished by the modification of a literature procedure in which 2, 2'- anhydro-1- ⁇ -D-arabmofuranosylurac ⁇ l was treated with 70% hydrogen fluoride-py ⁇ dme. Standard procedures were used to obtain the 5' -DMT and 5' -DMT-3'phosphoramidites.
- 2' -deoxy-2' -fluorocytidme was synthesized via ammation of 2 ' -deoxy-2 ' -fluorouridme, followed by selective protection to give N 4 -benzoyl-2' -deoxy-2 ' -fluorocytidme. Standard procedures were used to obtain the 5' -DMT and 5'-DMT-
- oligonucleotides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol .
- 2'- (2-methoxyethyl) -modified amidites are synthesized according to Martin, P., Helv. Chim . Acta 1995, 78,486-504.
- the last nucleotide was a deoxynucleotide. All 2' -0-CH 2 CH 2 OCH 3 .cytosines were 5-methyl cytosines. Synthesis of 5 -Methyl cytosine monomers :
- a first solution was prepared by dissolving 3'-0-acetyl- 2' -0-methoxyethyl-5' -O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH 3 CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH 3 CN (1 L) , cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl 3 was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours.
- the first solution was added dropwise, over a 45 minute period, to the later solution.
- the resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHC0 3 and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.
- Oligomers having methylene (methylimino) backbones are synthesized according to U.S. Patent 5,378,825, which is coassigned to the assignee of the present invention and is incorporated herein in its entirety. Synthesis is done as follows:
- the crude product was purified by silica gel chromatography (elution with CH 2 C1 2 :MeOH; 92:8, v/v) to furnish the title compound, 3' -De (oxyphosphinico) -3' - (methylidynenitrilo) thymidylyl- (3 ' ⁇ 5') -thymidine, (0.87 g, 89%) as a mixture of E/Z isomers.
- the two geometrical isomers were separated by reverse phase HPLC (Supelcosil LC18, 5 ⁇ , H 2 0:CH 3 CN gradient) .
- the isomeric dimer was further dimethyoxytrityled at the hydroxyl group of the 5' terminus nucleoside followed by conversion to its 3 ' -O- ⁇ -cyanoethyldiisopropylphosphoramidite derivative at the hydroxyl group at the 3' terminus nucleoside of the dimer following the procedure described in Oligonucleotide Synthesis: a practical approach, Ed. M.J. Gait, IRL Press, 1984, to yield the title compound.
- the protected dimer can be conveniently stored and used for coupling utilizing an automated DNA synthesizer (ABI 380B) as and when required for specific incorporation into oligomers of therapeutic value.
- an automated DNA synthesizer (ABI 380B) as and when required for specific incorporation into oligomers of therapeutic value.
- the oxime linked dimer is reduced to a dimer bearing a corresponding hydroxylamine linkage and this in turn can be alkylated to a hydroxylmethylamine or other hydroxyalkylamine linkage.
- This dimer was further purified by HPLC (as described for the 3 ' -de (oxyphosphinico) -3 ' - (methylidynenitrilo) thymidylyl - (3' ⁇ 5' ) -thymidine dimer) to obtain an analytically pure sample.
- l E NMR (DMSO-d 6 ) ⁇ 11.23 (br s, 2, 2NH) , 7.83 and 7.49 (2s, 2, 2C 6 H) , 6.82 (t, 1, NHO) , 6.14 (pseudo t, 1, T2 H x ., J x . ⁇ 2 .
- the 3 ' -de (oxyphosphinico) -3'- [methylene (methylimino) ] - thymidylyl- (3' ⁇ 5') thymidine dimer was tritylated and phosphitylated as described in Oligonucleotide Synthesis: a practical approach, Ed. M.J.
- the protected dimer was purified by silica gel column chromatography (CH 2 C1 2 :MeOH:Et 3 N; 9:1:0.1, v/v) and homogenous fractions were pooled and evaporated to furnish pure 3' -de(oxyphosphinico) -3' - [methylene (methylimino) ] - thymidylyl-5' -O- (dimethoxytriphenylmethyl) - (3' ⁇ 5' ) -3' -O- ( ⁇ - cyanoethyldiisopropylaminophosphiryl) thymidine as a white foam (used as such for DNA synthesis) .
- the above protected phosphoramidate bearing dimer can be conveniently stored and used for coupling utilizing an automated DNA synthesizer (ABI 380B) as and when required for specific incorporation into oligomers of therapeutic value.
- Other dimers of the inventions as for example but not limited the above noted methylidynenitrilo, i.e., oxime, and methyleneimino, i.e., aminohydroxy, dimers are converted to their corresponding phosphoramidate derivatives in the same manner as this example and incorporated into oligonucleotide in the standard manner as noted below.
- An oligomer bearing the oxime linked nucleoside dimer is reduced to an oligomer bearing a corresponding hydroxylamine linked nucleoside dimer.
- reduction can be effected as an CPG bound oligomer or after removal from the CPG.
- PNA Peptide-nucleic acid
- Example 2 Cells and cell culture HUVECs were purchased from Clonetics Corp. (San Diego CA) and grown in the suggested EBM medium supplemented with 10% fetal bovine serum (from HyClone, Logan UT) . Cells were used in experiments from passages two to ten at 80-90% confluency.
- OPTI-MEM OPTI-MEM, serially diluted to the desired concentrations and applied to washed cells. Basal and untreated (no oligomer) control cells were also treated with LIPOFECTIN. Cells were incubated for 4 hours at 37°C, at which time the medium was replaced with standard growth medium with or without 5 ng/ml TNF- ⁇ . In some experiments the cytokine medium was removed after one hour and replaced with standard medium. Incubation at 37°C was continued until the indicated times.
- FACS fluorescence activated cell sorting
- Nuclei were pelleted at lOOOx g, and the resulting supernatant was layered on a 10 to 35% (wt/vol) linear sucrose gradient (4 ml) with a 50% cushion (0.75 ml), in gradient buffer (10 mM Tris pH 8.0, 50 mM KOAc, 1 mM MgOAc, ImM DTT) . Gradients were centrifuged at 35,000 rpm for 3 hours at 5°C with a Beckman SW55Ti rotor. 250 ⁇ l fractions were collected with an Isco model 185 density gradient fractionator connected to a Pharmacia UV monitor and fraction collector.
- Example 7 ELISA screening of oligomers for activity against E-selectin gene expression:
- Opti-MEM Opti-MEM
- oligomer diluted in Opti-MEM containing 10 ⁇ g/ml DOTMA solution (Bethesda Research Labs, Bethesda MD) for 4 hours at 37°C.
- the medium was removed and replaced with EGM- UV (Clonetics, San Diego CA) plus oligomer.
- Tumor necrosis factor a was added to the medium (2.5 ng/ml) and the cells were incubated an additional 4 hours at 37°C.
- E-selectin expression was determined by ELISA. Cells were gently washed three times with Dulbecco's phosphate-buffered saline (D-PBS) prewarmed to 37°C. Cells were fixed with 95% ethanol at 4°C for 20 minutes, washed three times with D-PBS and blocked with 2% BSA in D-PBS. Cells were incubated with E- selectin monoclonal antibody BBA-1 (R&D Systems, Minneapolis MN) diluted to 0.5 ⁇ g/ml in D-PBS containing 2% BSA for 1 hour at 37°C.
- D-PBS Dulbecco's phosphate-buffered saline
- the concentration of the product was determined by measuring the absorbance at 575 nm in an ELISA microtiter plate reader.
- Example 8 ELISA assay for inhibition of HCMV replication by antisense oligonucleotides
- Oligonucleotides complementary to human cytomegalovirus mRNA were tested for antiviral activity in an ELISA-based assay of HCMV replication. Normal human dermal fibroblasts
- the secondary antibody biotinylated goat anti-mouse IgG (Bethesda Research Labs, MD) , was diluted 1:1000 in PBS with 1% BSA, and incubated with cells for one hour at 37°C. Cells were then washed and incubated for one hour at 37°C in streptavidin-B-D-galactosidase. Color was developed with chlorophenol red-B-D-galactopyranoside, 20 mg dissolved in 10 ml of 50 mM Na Phosphate, 1.5 mM MgCl2 ; plates were shaken for 10 minutes and the absorbance was read at 575 nm.
- Example 10 Western blot analysis of inhibition of expression of IE1 and IE2 protein products Stably transfected U373 neuroblastoma cells were used, each expressing a single CMV protein product. Cells were plated at 4.5 x 10 5 cells/well of a 6 well plate to obtain 55- 70% confluence the following day. Cells were treated with oligonucleotide at a concentration of 75 nM, with 5 ⁇ g/ml lipofectin, in OPTIMEM for 4 hours. Cells were refed with medium without oligonucleotide and allowed to recover overnight.
- Cells were harvested 16-20 hr post-treatment, washed once with PBS, suspended in Laemmli buffer (lOO ⁇ l/well) , boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels were run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Primary antibody was anti IE 55-72-86 antibody (Virostat) diluted 1:1000 and secondary antibody was radiolabelled goat anti-mouse. Bands were visualized using a PHOSPHORIMAGER (Molecular Dynamics, Sunnyvale CA) .
- Example 11 Electroporation of U937 cells with MMI oligomers
- U937 cells were washed once in cold Opti-MEM (Gibco-BRL, Grand Island, NY) and resuspended at 4 x 10 6 cells/ml. Oligomer was added to 0.1 ml of cells and incubated for 10 minutes on ice. Cells were transferred to a 1 mm gap electrode (BTX, San Diego, CA) and electroporated at 0. 75kV/cm. Cells were incubated at room temperature for 10 minutes and transferred to pre-warmed medium. Cells were allowed to rest for 1.5 hours before ICAM-1 expression was induced with 5 ng/ml TNF- ⁇ overnight. Cells were stained with an anti-ICAM-1-PE antibody (Pharmingen, San Diego CA) the next day.
- Opti-MEM Gibco-BRL, Grand Island, NY
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU27474/97A AU712228B2 (en) | 1996-05-24 | 1997-04-29 | Compositions and methods for antisense inhibition of protein translation |
EP97921438A EP0918787A4 (en) | 1996-05-24 | 1997-04-29 | Compositions and methods for antisense inhibition of protein translation |
CA002256358A CA2256358A1 (en) | 1996-05-24 | 1997-04-29 | Compositions and methods for antisense inhibition of protein translation |
JP9532955A JPH11513889A (en) | 1996-05-24 | 1997-04-29 | Compositions and methods for antisense inhibition of protein translation |
NZ332999A NZ332999A (en) | 1996-05-24 | 1997-04-29 | Compositions and methods for antisense inhibition of protein translation by preventing the formation of the capped mRNA ribosome complex |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/653,653 | 1996-05-24 | ||
US08/653,653 US5789573A (en) | 1990-08-14 | 1996-05-24 | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/653,653 Continuation-In-Part US5789573A (en) | 1990-08-14 | 1996-05-24 | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09194230 A-371-Of-International | 1999-02-24 | ||
US09/808,680 Continuation US20020052331A1 (en) | 1990-08-14 | 2001-03-15 | Compositions and methods for antisense inhibition of protein translation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997045437A1 true WO1997045437A1 (en) | 1997-12-04 |
Family
ID=24621781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/007132 WO1997045437A1 (en) | 1996-05-24 | 1997-04-29 | Compositions and methods for antisense inhibition of protein translation |
Country Status (7)
Country | Link |
---|---|
US (1) | US5789573A (en) |
EP (1) | EP0918787A4 (en) |
JP (1) | JPH11513889A (en) |
AU (1) | AU712228B2 (en) |
CA (1) | CA2256358A1 (en) |
NZ (1) | NZ332999A (en) |
WO (1) | WO1997045437A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1071699A1 (en) * | 1998-04-17 | 2001-01-31 | Isis Pharmaceuticals, Inc. | Enhanced antisense modulation of icam-1 |
EP1080225A1 (en) * | 1998-05-21 | 2001-03-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
EP1090025A1 (en) * | 1998-06-26 | 2001-04-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of tnfr1 expression |
US6277982B1 (en) * | 1999-08-20 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates |
DE10019252A1 (en) * | 2000-04-18 | 2001-10-31 | Klaus Karl Degitz | Polydeoxyribonucleotides to inhibit ICAM-1 gene expression |
US9701943B2 (en) | 2011-04-15 | 2017-07-11 | Cecilia Nauclér | Genetic variant of cytomegalovirus (CMV) |
US11473083B2 (en) | 2015-12-21 | 2022-10-18 | Novartis Ag | Compositions and methods for decreasing tau expression |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
US6153595A (en) * | 1990-08-16 | 2000-11-28 | Isis Pharmaceuticals Inc. | Composition and method for treatment of CMV infections |
US8153602B1 (en) * | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
US6399297B1 (en) * | 1998-10-06 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs) |
US7083786B2 (en) * | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
AU3762699A (en) * | 1998-04-27 | 1999-11-16 | Pacific Northwest Cancer Foundation | (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
US6197584B1 (en) * | 1998-05-01 | 2001-03-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD40 expression |
US5962672A (en) * | 1998-09-18 | 1999-10-05 | Isis Pharmaceuticals Inc. | Antisense modulation of RhoB expression |
US6001652A (en) * | 1998-09-18 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of cREL expression |
US5959097A (en) * | 1998-11-20 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEK2 expression |
US5977341A (en) * | 1998-11-20 | 1999-11-02 | Isis Pharmaceuticals Inc. | Antisense modulation of inhibitor-kappa B kinase-beta expression |
US5962673A (en) * | 1998-11-20 | 1999-10-05 | Isis Pharmaceuticals Inc. | Antisense modulation of inhibitor-kappa B kinase-alpha expression |
US5981732A (en) * | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
US6037142A (en) * | 1999-02-23 | 2000-03-14 | Isis Pharmaceuticals Inc. | Antisense inhibition of SMAD2 expression |
DE60020677T2 (en) | 1999-02-26 | 2006-05-04 | Chiron Corp., Emeryville | MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES |
EP1165771A2 (en) * | 1999-03-17 | 2002-01-02 | The University Of Tennessee Research Corporation | Rt-pcr of clonal neurospheres |
US6046321A (en) * | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
US6013788A (en) * | 1999-04-09 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense modulation of Smad3 expression |
US6806363B1 (en) * | 1999-04-16 | 2004-10-19 | Mayo Foundation For Medical Education & Research | Cobalamin conjugates useful as antitumor agents |
US6656730B1 (en) * | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6037176A (en) * | 1999-06-25 | 2000-03-14 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin beta 3 expression |
US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
US6187545B1 (en) * | 2000-01-19 | 2001-02-13 | Isis Pharmaceuticals Inc. | Antisense modulation of pepck-cytosolic expression |
US6180353B1 (en) * | 2000-01-24 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense modulation of daxx expression |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
WO2002000174A2 (en) | 2000-06-28 | 2002-01-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20020151525A1 (en) * | 2000-10-25 | 2002-10-17 | Collins Douglas A. | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation |
CA2446788A1 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
CA2448567C (en) | 2001-05-25 | 2014-05-20 | Duke University | Modulators of nucleic acid ligands |
US20060074034A1 (en) * | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
CA2476755C (en) | 2001-12-17 | 2014-08-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
WO2003097658A2 (en) | 2002-05-16 | 2003-11-27 | Glycomimetics, Inc. | Compounds and methods for inhibiting selectin-mediated function |
KR100440725B1 (en) * | 2002-06-20 | 2004-07-15 | 주식회사 그린진 바이오텍 | A Method for Increasing an Abiotic-Resistance in Monocot Plants |
AU2003245595A1 (en) * | 2002-07-03 | 2004-01-23 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
AU2003300776A1 (en) * | 2002-09-09 | 2004-05-25 | Omeros Corporation | G protein coupled receptors and uses thereof |
US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
US20040219158A1 (en) * | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
SI1625166T1 (en) | 2003-05-12 | 2015-08-31 | Helion Biotech Aps | Antibodies to masp-2 |
US20050054847A1 (en) * | 2003-08-01 | 2005-03-10 | Invitrogen Corporation | Compositions and methods for preparing short RNA molecules and other nucleic acids |
WO2005014796A2 (en) | 2003-08-08 | 2005-02-17 | Invitrogen Corporation | Methods and compositions for seamless cloning of nucleic acid molecules |
US20050287668A1 (en) * | 2003-11-04 | 2005-12-29 | Cell Therapeutics, Inc. (Cti) | RNA interference compositions and screening methods for the identification of novel genes and biological pathways |
EP1763533B1 (en) * | 2003-11-19 | 2008-01-09 | GlycoMimetics, Inc. | Specific antagonist for both e- and p-selectins |
US7455840B2 (en) * | 2003-11-19 | 2008-11-25 | The Scripps Research Institute | Compositions and methods to reduce mutagenesis |
CA2546784A1 (en) * | 2003-11-19 | 2005-06-16 | Glycomimetics, Inc. | Glycomimetic antagonists for both e- and p-selectins |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
CA2573144C (en) | 2004-06-10 | 2014-07-22 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2005123776A1 (en) * | 2004-06-10 | 2005-12-29 | Omeros Corporation | Methods for treating conditions associated with lectin-dependent complement activation |
AU2006216514C1 (en) * | 2005-02-25 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to IL-4R alpha |
US7585968B2 (en) * | 2005-03-28 | 2009-09-08 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to thymus and activation-regulated chemokine (TARC) |
US20090036386A1 (en) * | 2005-05-25 | 2009-02-05 | Glycomimetics, Inc | Heterobifunctional compounds for selectin inhibition |
AU2006280101B2 (en) * | 2005-08-09 | 2012-06-28 | Glycomimetics, Inc. | Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas |
PT1934236E (en) | 2005-09-02 | 2012-12-26 | Glycomimetics Inc | Heterobifunctional pan-selectin inhibitors |
EP1969143A4 (en) * | 2005-12-20 | 2009-07-22 | Isis Pharmaceuticals Inc | Double stranded nucleic acid molecules targeted to il-4 receptor alpha |
US20090176717A1 (en) * | 2006-06-01 | 2009-07-09 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
CA2666103C (en) | 2006-10-12 | 2014-02-18 | Glycomimetics, Inc. | Glycomimetic replacements for hexoses and n-acetyl hexosamines |
US20080293053A1 (en) * | 2006-12-28 | 2008-11-27 | The Regents Of The University Of Michigan | shRNA Materials and Methods of Using Same for Inhibition of DKK-1 |
NZ598863A (en) * | 2007-02-09 | 2013-11-29 | Glycomimetics Inc | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
JP5580192B2 (en) | 2007-03-27 | 2014-08-27 | オメロス コーポレーション | Use of PDE7 inhibitors for the treatment of movement disorders |
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
US8916531B2 (en) | 2007-11-20 | 2014-12-23 | Isis Pharmaceuticals, Inc. | Modulation of CD40 expression |
EP4074344A1 (en) | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
AU2008336249B2 (en) * | 2007-12-10 | 2015-01-29 | The University Of Queensland | Treatment and prophylaxis |
US20110117125A1 (en) | 2008-01-02 | 2011-05-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for the delivery of nucleic acids |
WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
US8341614B2 (en) * | 2008-06-06 | 2012-12-25 | Apple Inc. | Memory management for closures |
EP2318015B1 (en) * | 2008-06-13 | 2013-08-07 | GlycoMimetics, Inc. | Treatment of cancers of the blood using selected glycomimetic compounds |
CN104119242B (en) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | The amino lipids of improvement and the method for delivering nucleic acid |
EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
US20120101148A1 (en) | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
CN102421441B (en) | 2009-05-01 | 2015-04-01 | 糖模拟物有限公司 | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
KR20180094137A (en) | 2009-05-05 | 2018-08-22 | 알닐람 파마슈티칼스 인코포레이티드 | Lipid compositions |
CA3045126A1 (en) | 2009-05-05 | 2010-11-11 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
US8158601B2 (en) | 2009-06-10 | 2012-04-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulation |
WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
AU2010306581B2 (en) | 2009-10-16 | 2015-03-19 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
CA2783372C (en) | 2009-12-07 | 2019-07-16 | Muthiah Manoharan | Compositions for nucleic acid delivery |
ES2749426T3 (en) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Nucleic Acid Administration Methods and Compositions |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
WO2012064667A2 (en) | 2010-11-08 | 2012-05-18 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP3287142B1 (en) | 2011-04-08 | 2021-08-04 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
JP2014527398A (en) | 2011-06-21 | 2014-10-16 | オンコファクター コーポレイション | Compositions and methods for cancer therapy and diagnosis |
WO2013049328A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
PL2794626T6 (en) | 2011-12-22 | 2020-11-02 | Glycomimetics, Inc. | E-selectin antagonist compounds |
KR20220045089A (en) | 2012-02-24 | 2022-04-12 | 아뷰터스 바이오파마 코포레이션 | Trialkyl cationic lipids and methods of use thereof |
WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
EP2928476B1 (en) | 2012-12-07 | 2018-02-14 | GlycoMimetics, Inc. | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
EP3019200B1 (en) | 2013-07-11 | 2022-03-23 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
BR112016008409B1 (en) | 2013-10-17 | 2021-06-15 | Omeros Corporation E University Of Leicester | USE OF A MASP-2 INHIBITORY AGENT THAT INHIBITS MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
HUE045542T2 (en) | 2014-12-03 | 2019-12-30 | Glycomimetics Inc | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
CN108472347B (en) | 2015-11-09 | 2023-09-05 | 奥默罗斯公司 | Methods for treating conditions associated with MASP-2 dependent complement activation |
KR102475622B1 (en) | 2016-01-05 | 2022-12-08 | 유니버시티 오브 레스터 | Methods for inhibiting fibrosis in a subject in need thereof |
US11045485B2 (en) | 2016-01-22 | 2021-06-29 | Glycomimetics, Inc. | Glycomimetic inhibitors of PA-IL and PA-IIL lectins |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
KR20200113290A (en) | 2016-03-31 | 2020-10-06 | 오메로스 코포레이션 | Methods for inhibiting angiogenesis in a subject in need thereof |
US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
CA3037850A1 (en) | 2016-10-07 | 2018-04-12 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
TWI818919B (en) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
WO2019108750A1 (en) | 2017-11-30 | 2019-06-06 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
CN111566117A (en) | 2017-12-29 | 2020-08-21 | 糖模拟物有限公司 | Heterobifunctional inhibitors of E-selectin and galectin-3 |
CA3091454A1 (en) | 2018-03-05 | 2019-09-12 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
CA3150458A1 (en) | 2019-08-14 | 2021-02-18 | Acuitas Therapeutics, Inc. | Improved lipid nanoparticles for delivery of nucleic acids |
KR20220110530A (en) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | MASP-2 Inhibitors and Methods of Use |
IL310547A (en) | 2021-08-05 | 2024-03-01 | Sanegene Bio Usa Inc | 1'-alkyl modified ribose derivatives and methods of use |
IL311139A (en) | 2021-09-01 | 2024-04-01 | Entrada Therapeutics Inc | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy |
US20230241224A1 (en) | 2021-09-22 | 2023-08-03 | Sanegene Bio Usa Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives and methods of use |
US20230227480A1 (en) | 2021-10-05 | 2023-07-20 | Sanegene Bio Usa Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
WO2023144798A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
WO2023164464A1 (en) | 2022-02-22 | 2023-08-31 | Sanegene Bio Usa Inc. | 5'-modified carbocyclic ribonucleotide derivatives and methods of use |
WO2024015796A1 (en) | 2022-07-11 | 2024-01-18 | Sanegene Bio Usa Inc. | Optimized 2'- modified ribose derivatives and methods of use |
WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
WO2024042160A1 (en) | 2022-08-26 | 2024-02-29 | Mitodicure Gmbh | Use of a therapeutic agent with sodium-hydrogen antiporter 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
KR960004931B1 (en) * | 1990-05-23 | 1996-04-18 | 아이시스 파마슈티칼스, 인코포레이티드 | Composition and method for modulating ran activity through modification of the 5'cap structure of ran |
US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5591720A (en) * | 1990-08-16 | 1997-01-07 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
ES2188581T3 (en) * | 1990-08-14 | 2003-07-01 | Isis Pharmaceuticals Inc | MODULATION BY OLIGONUCLEOTIDOS OF THE CELL ADHERENCE. |
NZ244820A (en) * | 1991-10-25 | 1994-01-26 | Isis Pharmaceuticals Inc | Oligonucleotide inhibitor of epstein-barr virus. |
EP1310555A3 (en) * | 1992-03-16 | 2003-08-27 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of protein kinase c |
US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
ATE218372T1 (en) * | 1993-04-01 | 2002-06-15 | Isis Pharmaceuticals Inc | ANTISENSE OLIGONNUCLEOTIDES THAT INTERFER WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION |
ES2128535T3 (en) * | 1993-05-12 | 1999-05-16 | Novartis Ag | NUCLEOSIDES AND OLIGONUCLEOTIDES WITH 2'-ETER GROUPS. |
US6380169B1 (en) * | 1994-08-31 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Metal complex containing oligonucleoside cleavage compounds and therapies |
-
1996
- 1996-05-24 US US08/653,653 patent/US5789573A/en not_active Expired - Lifetime
-
1997
- 1997-04-29 NZ NZ332999A patent/NZ332999A/en not_active IP Right Cessation
- 1997-04-29 JP JP9532955A patent/JPH11513889A/en active Pending
- 1997-04-29 WO PCT/US1997/007132 patent/WO1997045437A1/en not_active Application Discontinuation
- 1997-04-29 CA CA002256358A patent/CA2256358A1/en not_active Abandoned
- 1997-04-29 EP EP97921438A patent/EP0918787A4/en not_active Withdrawn
- 1997-04-29 AU AU27474/97A patent/AU712228B2/en not_active Ceased
Non-Patent Citations (4)
Title |
---|
BAKER B F, ET AL.: "2'-O-(2-METHOXY)ETHYL-MODIFIED ANTI-INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1) OLIGONUCLEOTIDES SELECTIVELY INCREASE THE ICAM-1 MRNA LEVEL AND INHIBIT FORMATION OF THE ICAM-1 TRANSLATION INITIATION COMPLEX IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 272, no. 18, 2 May 1997 (1997-05-02), US, pages 11994 - 12000, XP002948752, ISSN: 0021-9258, DOI: 10.1074/jbc.272.18.11994 * |
BENNETT C F, ET AL.: "INHIBITION OF ENDOTHELIAL CELL ADHESION MOLECULE EXPRESSION WITH ANTISENSE OLIGONUCLEOTIDES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 152, 1 January 1994 (1994-01-01), US, pages 3530 - 3540, XP002948757, ISSN: 0022-1767 * |
KUMASAKA T, ET AL.: "ROLE OF THE INTERCELLULAR ADHESION MOLECULE-1 (ICAM-1) IN ENDOTOXIN-INDUCED PNEUMONIA EVLUATED USING ICAM-1 ANTISENSE OLIGONUCLEOTIDES, ANTI-ICAM-1 MONOCLONAL ANTIBODIES, AND ICAM-1 MUTANT MICE", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 97, no. 16, 1 May 1996 (1996-05-01), US, pages 2362 - 2369, XP002948753, ISSN: 0021-9738, DOI: 10.1172/JCI118679 * |
See also references of EP0918787A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1071699A1 (en) * | 1998-04-17 | 2001-01-31 | Isis Pharmaceuticals, Inc. | Enhanced antisense modulation of icam-1 |
EP1071699A4 (en) * | 1998-04-17 | 2002-05-29 | Isis Pharmaceuticals Inc | Enhanced antisense modulation of icam-1 |
EP1080225A1 (en) * | 1998-05-21 | 2001-03-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
EP1090025A1 (en) * | 1998-06-26 | 2001-04-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of tnfr1 expression |
EP1090025A4 (en) * | 1998-06-26 | 2003-11-26 | Isis Pharmaceuticals Inc | Antisense modulation of tnfr1 expression |
US6277982B1 (en) * | 1999-08-20 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates |
DE10019252A1 (en) * | 2000-04-18 | 2001-10-31 | Klaus Karl Degitz | Polydeoxyribonucleotides to inhibit ICAM-1 gene expression |
US9701943B2 (en) | 2011-04-15 | 2017-07-11 | Cecilia Nauclér | Genetic variant of cytomegalovirus (CMV) |
US11473083B2 (en) | 2015-12-21 | 2022-10-18 | Novartis Ag | Compositions and methods for decreasing tau expression |
Also Published As
Publication number | Publication date |
---|---|
AU2747497A (en) | 1998-01-05 |
CA2256358A1 (en) | 1997-12-04 |
US5789573A (en) | 1998-08-04 |
EP0918787A4 (en) | 2001-10-04 |
EP0918787A1 (en) | 1999-06-02 |
AU712228B2 (en) | 1999-11-04 |
NZ332999A (en) | 1999-11-29 |
JPH11513889A (en) | 1999-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU712228B2 (en) | Compositions and methods for antisense inhibition of protein translation | |
JP3121599B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
EP1035870B1 (en) | Compositions and methods for treatment of hepatitis c virus-associated diseases | |
KR100363475B1 (en) | Antisense Oligonucleotide Inhibition of ras | |
US6077833A (en) | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | |
US6391636B1 (en) | Antisense oligonucleotide modulation of raf gene expression | |
JP2002526093A (en) | Antisense modulation of bcl-x expression | |
SK109198A3 (en) | Sugar-modified gapped oligonucleotides | |
WO1999027134A1 (en) | Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression | |
US5981731A (en) | Antisense oligonucleotide modulation of B-raf gene expression | |
JP2006028188A (en) | Antisense modulation of survivin expression | |
JP2002539073A (en) | Antisense modulation of Survivin expression | |
CA2285921C (en) | Composition and method for treatment of cmv infections | |
JP2003531630A (en) | Antisense modulation of DNA binding inhibitor-1 expression | |
EP0928419A1 (en) | Compositions and methods for modulating type i interleukin-1 receptor expression | |
EP0979309A1 (en) | Oligonucleotides for enhanced bioavailability | |
EP0691853B1 (en) | ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION | |
US20020052331A1 (en) | Compositions and methods for antisense inhibition of protein translation | |
JP2002519015A (en) | Antisense modulation of TNFR1 expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2256358 Country of ref document: CA Ref country code: CA Ref document number: 2256358 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 532955 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 332999 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997921438 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997921438 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997921438 Country of ref document: EP |